
Please try another search
Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the clinical development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. Its Sulforadex technology enables sulforaphane to be delivered as a stable, solid, active ingredient in an oral pharmaceutical product. Its lead drug, SFX-01, exploits sulforaphane’s activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. The Company pipeline includes SFX-01 and breast cancer, SFX-01 and glioma, and SFX-01 and SHP2. SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The Company is also researching a range of synthetic, stabilized novel analogues of sulforaphane to advance the pharmaceuticals.
Name | Age | Since | Title |
---|---|---|---|
Barry Clare | 68 | 2014 | Non-Executive Chairman |
Richard Anthony Moulson | 60 | 2017 | CFO & Executive Director |
Alan Barge | - | 2015 | Independent Non-Executive Director |
Susan Elizabeth Clement-Davies | 59 | 2018 | Independent Non-Executive Director |
Huw Jones | 62 | 2020 | CEO & Executive Director |
Susan Elizabeth Foden | 69 | 2014 | Senior Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review